ProCE Banner Activity

FLYER: Phase III Trial of R-CHOP x 4 Followed by Rituximab x 2 vs R-CHOP x 6 in Younger Patients With Favorable-Prognosis DLBCL

Slideset Download
Conference Coverage
Efficacy with R-CHOP x 4 → R x 2 was noninferior to R-CHOP x 6 with a decrease in the number of nonhematologic adverse events by approximately one third.

Released: December 03, 2018

Expiration: December 02, 2019

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Celgene

Dova Pharmaceuticals

Gilead Text

Incyte

Janssen Biotech Pharmacyclics Abbvie

Jazz Pharmaceuticals Inc

Novartis Pharmaceuticals Corporation

Seagen

Takeda Oncology